Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 3/2006

01-05-2006 | Original Article

Serum lipid profile in fibromyalgia women

Authors: Gulcan Gurer, Omer Faruk Sendur, Cavidan Ay

Published in: Clinical Rheumatology | Issue 3/2006

Login to get access

Abstract

The etiology and pathogenic mechanisms of fibromyalgia (FM) syndrome are unknown. A number of studies have shown that there is an association between some of the musculoskeletal system diseases and hyperlipidemia. The aims of this study were (1) to compare the serum lipid profile among FM and healthy women and (2) to investigate the relationship between serum lipid levels and FM findings. One hundred sixty-four women (82 women with FM as study group and 82 healthy women as control group) were enrolled in the study. The mean serum total cholesterol and low-density lipoprotein cholesterol (LDL-c) were found significantly higher in the FM group than that in the control group (p<0.05). However, There was no statistically significant difference in the mean serum triglyceride, high-density lipoprotein cholesterol (HDL-c), and very low-density lipoprotein cholesterol (VLDL-c) values between the two groups (p>0.05). In the FM group, we could not find a significant correlation between the serum lipid profile values and the FM parameters (p>0.05).
Literature
1.
Bernatsky S, Dobkin PL, De Civita M, Penrod JR (2005) Co-morbidity and physician use in fibromyalgia. Swiss Med Wkly 135:76–81PubMed
2.
McCarberg B, Barkin RL, Wright JA, Cronan TA, Groessl E, Schmidt SM (2003) Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. Am J Ther 10:176–192CrossRefPubMed
3.
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28PubMedCrossRef
4.
White KP, Speechley M, Harth M, Ostbye T (1999) The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 26:1570–1576PubMed
5.
Alarcon GS, Bradley LA (1998) Advances in the treatment of fibromyalgia: current status and future directions. Am J Med Sci 315:397–404CrossRefPubMed
6.
Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC (1999) A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 21:180–191PubMedCrossRef
7.
Thomas E, Blotman F (2002) Are antidepressants effective in fibromyalgia? Joint Bone Spine 69:531–533CrossRefPubMed
8.
Cedraschi C, Desmeules J, Rapiti E, Baumgartner E, Cohen P, Finckh A, Allaz AF, Vischer TL (2004) Fibromyalgia: a randomised, controlled trial of a treatment programme based on self management. Ann Rheum Dis 63:290–296CrossRefPubMed
9.
Klemp P, Halland AM, Majoos FL, Steyn K (1993) Musculoskeletal manifestations in hyperlipidemia: a controlled study. Ann Rheum Dis 52:44–48PubMed
10.
Careless DJ, Cohen MG (1993) Rheumatic manifestations of hyperlipidemia and antihyperlipidemia drug therapy. Semin Arthritis Rheum 23:90–98PubMedCrossRef
11.
Struthers GR, Scott DL, Bacon PA, Walton KW (1983) Musculoskeletal disorders in patients with hyperlipidemia. Ann Rheum Dis 42:519–523PubMed
12.
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172PubMedCrossRef
13.
Burkhardt CS, Clark SR, Bennett RM (1991) The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 18:728–733PubMed
14.
Hedin PJ, Hamme M, Burkhardt CS, Engstrom-Laurent A (1995) The Fibromyalgia Impact Questionnaire, a Swedish translation of a new tool for evaluation of the fibromyalgia patient. Scand J Rheumatol 24:69–75PubMedCrossRef
15.
Buskila D, Neumann L (1996) Assessing functional disability and health status of women with fibromyalgia: validation of a Hebrew version of the Fibromyalgia Impact Questionnaire. J Rheumatol 23:903–906PubMed
16.
Offenbaecher M, Waltz M, Schoeps P (2000) Validation of a German version of the Fibromyalgia Impact Questionnaire (FIQ-G). J Rheumatol 27:1984–1988PubMed
17.
Sarmer S, Ergin S, Yavuzer G (2000) The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 20:9–12CrossRefPubMed
18.
Ozgocmen S, Ardicoglu O (2000) Lipid profile in patients with fibromyalgia and myofascial pain syndromes. Yonsei Med J 41:541–545PubMed
19.
Hacettepe University Institute of Population Studies (2004), General Directorate of Mother and Child Health/Family Planning. Ministry of Health, Ankara, Turkey, p 65
20.
Keel P (1999) Pain management strategies and team approach. Baillieres Best Pract Res Clin Rheumatol 13:493–506CrossRefPubMed
21.
Sim J, Adams N (1999) Physical and other non-pharmacological interventions for fibromyalgia. Baillieres Best Pract Res Clin Rheumatol 13:507–523CrossRefPubMed
22.
Oliver K, Cronan T (2002) Predictors of exercise behaviors among fibromyalgia patients. Prev Med 35:383–389PubMedCrossRef
23.
Bennett RM, Clark SR, Goldberg L, Nelson D, Bonafede RP, Porter J, Specht D (1989) Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 32:454–460PubMedCrossRef
24.
Aguilo A, Tauler P, Pilar Guix M, Villa G, Cordova A, Tur JA, Pons A (2003) Effect of exercise intensity and training on antioxidants and cholesterol profile in cyclists. J Nutr Biochem 14:319–325CrossRefPubMed
25.
Hardman AE (1996) Exercise in the prevention of atherosclerotic, metabolic and hypertensive diseases: a review. J Sports Sci 14:201–218CrossRefPubMed
26.
Wood PD (1994) Physical activity, diet, and health: independent and interactive effects. Med Sci Sports Exerc 26:838–843PubMed
27.
Brites FD, Evelson PA, Christiansen MG, Nicol MF, Basílico MJ, Wikinski RW, Llesuy SF (1999) Soccer players under regular training show oxidative stress but an improved plasma antioxidant status. Clin Sci 96:381–385CrossRefPubMed
Metadata
Title
Serum lipid profile in fibromyalgia women
Authors
Gulcan Gurer
Omer Faruk Sendur
Cavidan Ay
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0004-5

Other articles of this Issue 3/2006

Clinical Rheumatology 3/2006 Go to the issue

Brief Report

Dramatical improvement of chemoresistant bone lymphoma with rituximab

Case Report

Hypertrophic pachymeningitis and undifferentiated connective tissue disease: a case report and review of the literature

Original Article

Evaluating the Korean version of the Multidimensional Health Assessment Questionnaire in patients with rheumatoid arthritis

Original Article

Wegener's granulomatosis: clinical and laboratory results of a university hospital study of 20 patients from Turkey

Original Article

Lipid peroxidation and trace elements in systemic sclerosis

Original Article

A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits